Study Findings on Peptides and Proteins Are Outlined in Reports from Mayo Clinic (Engineering theranostic nanovehicles capable of targeting cerebrovascular amyloid deposits)
By a News Reporter-Staff News Editor at Biotech Week -- Data detailed on Proteins have been presented. According to news reporting out of Rochester, Minnesota, by NewsRx editors, research stated, "Cerebral amyloid angiopathy (CAA) is characterized by the deposition of amyloid beta (A beta) proteins within the walls of the cerebral vasculature with subsequent aggressive vascular inflammation leading to recurrent hemorrhagic strokes. The objective of the study was to develop theranostic nanovehicles (TNVs) capable of a) targeting cerebrovascular amyloid; b) providing magnetic resonance imaging (MRI) contrast for the early detection of CAA; and c) treating cerebrovascular inflammation resulting from CAA."
Our news journalists obtained a quote from the research from Mayo Clinic, "The TNVs comprised of a polymeric nanocore made from Magnevist ® (MRI contrast agent) conjugated chitosan. The nanocore was also loaded with cyclophosphamide (CYC), an immunosuppressant shown to reduce the cerebrovascular inflammation in CAA. Putrescine modified F(ab')(2) fragment of anti-amyloid antibody, IgG4.1 (pF(ab')(2)4.1) was conjugated to the surface of the nanocore to target cerebrovascular amyloid. The average size of the control chitosan nanoparticles (conjugated with albumin and are devoid of Magnevist ®, CYC, and pF(ab')(2)4.1) was 164 +/- 1.2 nm and that of the TNVs was 239 +/- 4.1 nm. The zeta potential values of the CCNs and TNVs were 21.6 +/- 1.7 mV and 11.9 +/- 0.5 mV, respectively. The leakage of Magnevist ® from the TNVs was a modest 0.2% over 4 days, and the CYC release from the TNVs followed Higuchi's model that describes sustained drug release from polymeric matrices. The studies conducted in polarized human microvascular endothelial cell monolayers (hCMEC/D3) in vitro as well as in mice in vivo have demonstrated the ability of TNVs to target cerebrovascular amyloid. In addition, the TNVs provided contrast for imaging cerebrovascular amyloid using MRI and single photon emission computed tomography."
According to the news editors, the research concluded: "Moreover, the TNVs were shown to reduce pro-inflammatory cytokine production by the A beta challenged blood brain barrier (BBB) endothelium more effectively than the cyclophosphamide alone."
For more information on this research see: Engineering theranostic nanovehicles capable of targeting cerebrovascular amyloid deposits. Journal of Controlled Release, 2014;185():121-129. Journal of Controlled Release can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Controlled Release - www.elsevier.com/wps/product/cws_home/502690)
Our news journalists report that additional information may be obtained by contacting E.K. Agyare, Mayo Clinic, Dept. of Radiol, Rochester, MN 55905, United States. Additional authors for this research include K.M. Jaruszewski, G.L. Curran, J.T. Rosenberg, S.C. Grant, V.J. Lowe, S. Ramakrishnan, A.K. Paravastu, J.F. Poduslo and K.K. Kandimalla (see also Proteins).
Keywords for this news article include: Amyloid, Proteins, Rochester, Minnesota, Engineering, Inflammation, United States, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC